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needs
Highlights
1. There is considerable controversy in the literature surrounding the diagnosis and treatment (including diet,
insulin therapy, and oral blood glucose lowering agents) of gestational diabetes mellitus, as well as the possible
long-term consequences for the offspring.
2. Worldwide different diagnostic criteria are used and discussion remains on the efﬁciency, and safety, of treatment
modalities.
3. There is clearly more need for GDM research. Gestational diabetes mellitus is a global health concern, because
its prevalence is high and on the increase, but also because of the potential implications for the health of mothers
and their offspring.
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Abstract
Gestational diabetes mellitus (GDM) is a global health concern, not only
because its prevalence is high and on the increase, but also because of the poten-
tial implications for the health of mothers and their offspring. Unfortunately,
there is considerable controversy in the literature surrounding the diagnosis
and treatment of GDM, as well as the possible long-term consequences for the
offspring. As a result, worldwide there is a lack of uniformly accepted diagnostic
criteria and the advice regarding the treatment of GDM, including diet, insulin
therapy, and the use of oral blood glucose-lowering agents, is highly variable. In
this review we provide an overview of the important issues in the ﬁeld of GDM,
including diagnostic criteria, different treatment regimens available, and the
long-term consequences of GDM in the offspring.
Keywords: diagnosis, diet, gestational diabetes mellitus, insulin, oral blood
glucose-lowering agents.
Introduction
Historically, gestational diabetes mellitus (GDM) was
deﬁned as any degree of glucose intolerance with an
onset or ﬁrst recognition during pregnancy. According
to the American Diabetes Association (ADA),1 GDM
is diabetes mellitus (DM) diagnosed in the second or
third trimester of pregnancy that does not clearly meet
the criteria of overt DM. For women diagnosed with
GDM in the ﬁrst trimester of pregnancy, pre-existing
DM should be strongly considered.1 Gestational
diabetes mellitus affects up to 14 % of all pregnancies,
depending on the diagnostic criteria used and the
population studied.2 Given the fact that both obesity
and DM are now worldwide epidemics, the prevalence
of GDM is still increasing.2–4
Untreated GDM carries a risk for both the mother
and child and is associated with serious short- and
long-term consequences, including neonatal and obste-
tric complications during pregnancy and childbirth (e.g.
macrosomia, birth injury, cesarean section5–7) and a
predisposition to obesity and DM in the offspring in
later life.8–10 Fortunately, studies have shown that many
of these consequences can be reduced by early detection
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and intervention.11,12 However, worldwide there is still a
lack of agreement on the best way to diagnose and treat
GDM. Different diagnostic criteria are used, and many
countries use their own recommendations. As a result,
discussion remains on the efﬁciency, and safety, of treat-
ment modalities for GDM, including the use of oral
blood glucose-lowering agents, as well as the possible
short- and long-term consequences for the offspring.
Hereinwe describe both the current knowledge regarding
GDMand the unmet needs of this condition.We review the
diagnostic criteria, different treatment regimens available,
and the consequences of GDM in the offspring.
Diagnostic criteria
The original diagnostic criteria for GDM were
established in 1964 by O’Sullivan and Mahan.13 Their
criteria were based on a 3-h 100-g oral glucose tolerance
test (OGTT) and were chosen to identify women at high
risk for development of diabetes after pregnancy.13 In
1979–80, the 2-h 75-g OGTT was introduced as diagnos-
tic test for non-pregnant diabetic individuals, and the
World Health Organization (WHO) advised that this
be used to diagnose diabetes in pregnant women, with
cut-off values for the diagnosis of GDM being fasting
plasma glucose (FPG) ≥7.8mmol/L and 2-h glucose
levels ≥11.1mmol/L.14,15 In 1997, the ADA proposed
to lower the FPG from 7.8 to 7.0mmol/L for
non-pregnant diabetic individuals.16 Two years later,
the WHO 1999 report on the deﬁnition, screening, and
diagnosis of GDM was the ﬁrst step to creating a univer-
sal guideline for GDM.17 In that report, the same fasting
glucose values for pregnant women were recommended
as proposed by the ADA.17 These diagnostic criteria
were not speciﬁcally intended to identify increased risk
of adverse neonatal and maternal outcomes.18
For decades, the degree of hyperglycemia that was
associated with increased risk of adverse neonatal and
maternal outcomes remained uncertain. In 2008, the
multinational prospective observational Hyperglycemia
and Adverse Pregnancy Outcome (HAPO) study
reported on the associations between FPG and 1- and
2-h plasma glucose values during an OGTT and the risk
of adverse neonatal and maternal outcomes.19 More
than 25 000 non-diabetic women with singleton pregnan-
cies underwent a 75-g OGTT at 24–32weeks gestation.
The study demonstrated a continuous association of
maternal glucose levels with increased rates of both the
predeﬁned primary adverse pregnancy outcomes (i.e.
birth weight > 90th percentile and cord blood serum
C-peptide levels >90th percentile) and the secondary
outcomes (i.e. premature delivery, shoulder dystocia or
birth injury, intensive neonatal care, hyperbilirubinemia,
and pre-eclampsia).19 As a result of these ﬁndings and
those from earlier observational studies,5,20–23 the diag-
nostic criteria of GDM were reconsidered worldwide,
and guidelines were adapted to include these more strin-
gent criteria. In 2010, the International Association of
the Diabetes and Pregnancy Study Groups (IADPSG)
published new criteria for the diagnosis of GDM, which
recommended the following 75-g OGTT glycemic
thresholds: fasting value ≥5.1mmol/L (92mg/dL); 1-h
value ≥10.0mmol/L (180mg/dL); and 2-h value
≥8.5mmol/L (153mg/dL).18 These values were chosen
because they predict an increased risk of adverse
pregnancy outcomes (deﬁned as a 75 % higher chance
of adverse outcomes vs normal glucose values). For the
other adverse outcomes of the HAPO study, no thres-
hold risk could be identiﬁed.18
The IADPSG criteria were adopted by the ADA in
201024 and by the WHO in 2013.14 However, the ADA
did not follow the one-step diagnostic approach recom-
mended by the IADPSG and left the door open for the
two-step screening strategy based on the National
Institutes of Health (NIH) consensus conference
report.24,25 The IADPSG’s one-step screening strategy
involves the use of a 75-g OGTT, whereby GDM is
diagnosed on the basis of one abnormal value for either
the fasting or the 2-h glucose level. The two-step scree-
ning strategy makes use of a non-fasting 50-g glucose
challenge test, whereby an abnormal test result (i.e. 1-h
value ≥7.8mmol/L) is followed by a 100-g OGTT.
Gestational diabetes mellitus is then diagnosed on the
basis of two abnormal values in this 100-g OGTT for
the fasting, 1-, 2-, or 3-h glucose levels, using either the
Carpenter and Coustan criteria26 or the National
Diabetes and Data Group criteria (Table 1).27
Worldwide, there is a lack of uniformly accepted
diagnostic criteria. The different criteria used by diffe-
rent expert groups are summarized in Table 1. The main
discrepancies in these guidelines relate to the use of FPG
values that are higher than those of the IADPSG criteria.
However, studies have shown that global adoption of the
IADSPG criteria would lead to an increase in the preva-
lence of GDM, which would result in a higher burden to
obstetric healthcare and higher costs.28–30 Other critics
of such a proposed change state that there is only limited
evidence for the beneﬁt of treatment of GDM diagnosed
according to thresholds proposed by the IADPSG
criteria (mild GDM), that the OGTT has poor reproduc-
ibility, and that data are lacking on the cost-effectiveness
of GDM treatment when diagnosed according to the
IADPSG criteria.31,32
The differences between the various guidelines in terms of
cut-off levels indicate the need for large cost–beneﬁt studies
of the treatment of GDM diagnosed according to the
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IADPSG criteria. Such studies may help overcome reluc-
tance for a broad implementation of strict diagnostic
criteria. Because the main reason for this reluctance cur-
rently appears to be economic healthcare concerns regard-
ing the burden of obstetric care, such studies will at least
provide us with international consensus.
Treatment
Two randomized controlled trials (RCTs) have investi-
gated the beneﬁts of screening and treatment of GDM
in terms of pregnancy complications.11,12 The ﬁrst was
conducted in 2005 by the Australian Carbohydrate
Intolerance Study in Pregnant Women (ACHOIS) Trial
Group.12 That study randomly assigned 1000 women
with GDM between 24 and 34weeks gestation to receive
either dietary advice, self-monitoring of blood glucose
(SMBG), and insulin therapy (intervention group) or
routine care (control group). Women in the routine care
(control) group replicated clinical care in which scree-
ning for GDM was not available. The study showed that
treatment of GDM reduced the frequency of serious
perinatal complications (deﬁned as perinatal death,
shoulder dystocia, bone fracture, and nerve palsy) and
improved the mother’s health-related quality of life.12
However, the women in the intervention group were
more likely to have labor induced than women in the
routine group, and more of the neonates in the interven-
tion group were admitted to the neonatal nursery.12
The second RCT was conducted in 2009 by Landon
et al.11 and included 958 mild GDM pregnancies
(deﬁned as a fasting glucose <5.3mmol/L) between 24
and 31weeks gestation. The women were assigned to
usual prenatal care (control group) or dietary advice,
SMBG, and insulin therapy (intervention group). The
study showed that although treatment of mild GDM
did not signiﬁcantly reduce the frequency of a composite
outcome that included stillbirth or perinatal death and
several neonatal complications, it did reduce the risk of
fetal overgrowth, shoulder dystocia, cesarean delivery,
and pregnancy hypertensive complications.11
Following on from these ﬁndings, several systematic
reviews and meta-analyses summarized the evidence of
the beneﬁts of treatment for women with GDM.33–37
These reviews included mainly the aforementioned trials,
but also additional studies that compared intensive treat-
ment, including diet modiﬁcation, glucose monitoring,
and/or insulin, or any therapeutic intervention of
GDM with usual obstetric care in women with GDM.
These reviews demonstrated not only that treatment of
GDM is effective, but that it also lowers the risk of
pre-eclampsia and several neonatal complications,
including macrosomia, shoulder dystocia, and neonates
born large for gestational age (LGA).33–37
Diet
Globally, the primary approach for GDM is dietary
advice in combination with SMBG. It is estimated that
dietary advice helps 70%–85 % of women with GDM
to obtain optimal glycemic control.38 Remarkably, there
are no speciﬁc guidelines for diet or exercise in GDM.
Nevertheless, there is consensus that the goal of dietary
advice should be to fulﬁll nutrient intake for normal
neonatal growth and to achieve optimal glycemic
control, without inducing weight loss or excessive weight
gain.39 Optimal glycemic control can be achieved by
following a diet that includes carbohydrate distribution
and a reduction in rapidly digested sugars.
Table 1 Overview of the currently used diagnostic criteria for gestational diabetes mellitus worldwide
WHO 199917
WHO 2013,14
IADPSG 201018 ADA 2015A,24 NICE 201598 ADIPS112
Carpenter and
Coustan26 NDDG27
Glucose levels (mmol/L [mg/dL])
Fasting ≥7.0 (≥128) ≥5.1 (≥92) ≥5.1 (≥92) ≥5.3 (≥95) ≥5.6 (≥100) ≥5.1 (≥92) ≥5.3 (≥95) ≥5.8 (≥105)
OGTT
1-h – ≥10.0 (≥180) ≥10.0 (≥180) ≥10.0 (≥180) ≥10.0 (≥180) ≥10.0 (≥180) ≥10.6 (≥190)
2-h ≥7.8 (≥140) ≥8.5 (≥153) ≥8.5 (≥153) ≥8.6 (≥155) ≥7.8 (≥140) ≥8.5 (≥153) ≥8.6 (≥155) ≥9.2 (≥165)
3-h – – – ≥7.8 (≥140) – ≥7.8 (≥140) ≥8.0 (≥145)
Total no. abnormal
values
≥1b ≥1b ≥1b ≥2c ≥1b ≥1b ≥2c ≥2c
aThe American Diabetes Association (ADA) 2015 recommendations leave the option open to use either the one-step International Association of
the Diabetes and Pregnancy Study Groups (IADPSG) recommendation or the two-step strategy, with the option in the two-step strategy of using
either the Carpenter and Coustan criteria or the National Diabetes and Data Group (NDDG) criteria.
bOn a 75-g oral glucose tolerance test (OGTT).
cOn a 100-g OGTT.
WHO, World Health Organization; NICE, National Institute for Health and Care Excellence; ADIPS, Australasian Diabetes in Pregnancy Society.
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Increasing attention is being paid to the effect of
different types of dietary intervention on pregnancy
outcomes in women with GDM. Such speciﬁc dietary
approaches include low-glycemic index (GI), energy re-
striction, and low-carbohydrate (LC) diets. A Cochrane
systematic review on the effects of different types of
dietary intervention in GDM found no effect for any
speciﬁc type of dietary intervention in terms of reducing
the following outcomes: instrumental deliveries, LGA
neonates, or neonates with a birth weight > 4000 g.40
However, this ﬁnding is in contrast with that of a more
recent systematic review on the type of dietary interven-
tions on maternal and neonatal outcomes in women with
GDM.41 That review included nine RCTs that had
studied different types of dietary advice. The authors
performed three meta-analyses according to the three
types of dietary intervention: low-GI diets (deﬁned as
GI <55); total energy restriction diets (deﬁned as 1600–
1800 kcal or ~33 % reduction in caloric intake); and
LC diets (<45 % of energy supply coming from carbohy-
drates). When the dietary interventions were compared
with the control diets, only a low-GI diet was associated
with beneﬁcial outcomes, such as less frequent insulin
use and lower neonatal weight. The study suggested that
a low-GI diet reduces the use of insulin because of its
ability to reduce postprandial glucose excursions.41
Apart from these meta-analyses on dietary interven-
tions, the role of LC diets in GDM has gained consider-
able attention. Low-carbohydrate diets are currently
popular in the general population and are widely used
to treat obesity.42 Evidence has shown that LC diets are
also effective in the treatment of diabetes, particularly if
the condition is complicated by insulin resistance.43,44
Consequently, more attention is being paid to the use of
an LC diet in GDM. However, evidence is lacking on
both the short- and long-term effects of an LC diet in
GDM, in terms of both blood glucose values and safety.
According to the National Academy of Medicine, the
minimum daily carbohydrate intake should be >130 g
for the general population and >175 g for pregnant
women.45 The additional 45 g/day carbohydrates are in-
dicated for neonatal brain development and functioning.
A carbohydrate intake <175 g can have negative conse-
quences for the neonate.46 Furthermore, to compensate
for the reduced carbohydrate intake, the intake of other
sources of nutrients, such as protein and fat, increases.
Because of an LC diet’s restricted food choices, there is
an increased risk of nutritional deﬁciencies. Therefore,
such diets may theoretically limit the consumption of
dietary ﬁber, vitamins, calcium, potassium, magnesium,
and iron.47
Two RCTs48,49 and one non-randomized trial50 that
investigated the short-term effectiveness of an LC diet
in GDM reported conﬂicting results. Two of the studies
showed postprandial glucose values were lower in
women on an LC diet (ranging from 40 % to 45 % in
the intervention group) than in women on a high-
carbohydrate diet (ranging from >45 % to 65 % in the
control group).49,50 Although neither of these studies
reported a reduction in fasting glucose values, in the
study by Major et al.50 the women with the lowest carbo-
hydrate intake (<42 %) required less additional insulin
therapy. However, in the RCT by Moreno-Castilla
et al.,48 an LC diet (intervention 40 % vs control 55 %)
did not signiﬁcantly reduce the need for insulin therapy.
A recent prospective cohort study in women with a
history of GDM51 investigated whether there was an as-
sociation between an LC diet and the long-term risk of
type 2 DM (T2DM). An LC diet with a high intake of
protein and fat mainly from animal-based foods was as-
sociated with a higher risk of T2DM, whereas an LC diet
with a high intake of protein and fat mainly from plant-
based foods was not. These ﬁndings suggest that women
with a history of GDM who follow an LC diet may re-
duce their future risk of T2DM by consuming plant-
rather than animal-based sources of protein and fat.51
In summary, there is general agreement on limiting
excessive carbohydrate intake and that carbohydrates
should be distributed equally throughout the day.
Although it is unknown whether carbohydrate restric-
tion is beneﬁcial in GDM, some studies have shown
beneﬁcial effects on glucose control and also on the risk
of developing T2DM after GDM.
Insulin
Women who receive dietary advice but fail to maintain
glycemic control within 1–2weeks generally receive
additional insulin therapy. Insulin therapy is the medica-
tion of choice in GDM and is recommended in almost all
international guidelines. Insulin is safe in pregnancy be-
cause it virtually does not cross the placental barrier
and it is not known to have any teratogenic effects.
The most frequently used types of insulin are regular
insulin (RI) and neutral protamine Hagedorn (NPH)
insulin, which are both completely homogeneous with
human insulin and therefore considered safe in preg-
nancy. A major drawback of RI is that its activity proﬁle
does not match that of physiological insulin. The onset
of action of RI begins between 30 and 60min after injec-
tion, reaching peak activity after 2–3 h and having an
effective working duration lasting up to 8–10 h.52 Not
only does it often peak too late to control postprandial
blood glucose values, but it also carries an increased risk
of hypoglycemia. To overcome this, rapid-acting insulin
analogs have been developed in which one of the amino
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acids is substituted to improve the pharmacokinetic
proﬁle. The action of rapid-acting insulin analogs (i.e.
lispro, aspart, and glulisine) begins 5–15min after injec-
tion, reaching peak activity between 30 and 90min and
having an effective working duration of 4–6 h.52 Rapid-
acting insulin analogs can therefore help achieve good
postprandial blood glucose values while minimizing the
risk of hypoglycemia.52
Both insulin aspart and lispro have been shown to be
effective in pre-existing DM but have not been studied
extensively in GDM.53–55 To date, few studies have
looked speciﬁcally at aspart and lispro in GDM.56–61 A
review by Lambert and Holt62 on the use of insulin
analogs in pregnancy showed that compared with RI,
the use of aspart and lispro is associated with better
maternal glycemic control and a similar fetal outcome.
No evidence of increased risk of congenital anomalies
has been reported.63 Because insulin aspart and lispro
are licensed for use during pregnancy in Europe, both
insulin lispro and insulin aspart can be safely adminis-
tered in pregnancy.
The use of NPH and the long-acting basal insulin
analogs has both advantages and disadvantages. A ma-
jor drawback of NPH insulin is that both its duration
of action and peak effect are intermediate. The action
of NPH begins 2–4 h after injection, its peak action effect
is between 4 and 10 h, and its effective working duration
is 12–18 h.52 Indeed, outside pregnancy, rates of noctur-
nal hypoglycemia are known to be higher for NPH insu-
lin than for long-acting analogs.64 The onset of action
for long-acting insulin analogs is 2–4 h after injection
and their effective duration is 16–20 h, with no peak ef-
fect.52 Insulin detemir has been approved by the US
Food and Drug Administration (FDA) for use during
pregnancy,65 and its use has shown no adverse preg-
nancy outcomes.66 The data on insulin glargine in preg-
nancy appear to be insufﬁcient because most of the
studies that have included this drug are small and retro-
spective.62 Furthermore, insulin glargine has insulin-like
growth factor (IGF)-1-binding properties, which could
be a disadvantage in pregnancy.63,67 However, as for
RI, insulin glargine does not to cross the placental bar-
rier.68 There is no evidence to support the use of insulin
glargine in GDM.
Oral blood glucose-lowering agents
In recent years, the use of oral blood glucose-lowering
agents has gained considerable interest as an alternative
for insulin therapy during pregnancy. Oral agents are
not only less expensive, but they are also more easy to
use, making them more patient friendly than insulin ther-
apy, which requires training in insulin injection technique
and demands time of healthcare providers.69 It has been
suggested that the oral blood glucose-lowering agents
glyburide and metformin can be used in pregnancy.
Glyburide is a second-generation sulfonylurea (SU)
that directly stimulates insulin secretion by binding to
the SU receptor on the cell membrane of pancreatic
β-cells. The major side effects of glyburide are an in-
creased risk of maternal hypoglycemia and weight gain.
There was a long-standing controversy as to whether
glyburide can cross the placental barrier. In earlier stu-
dies glyburide, was not detected in the cord blood of the
neonates,70,71 but this was rejected by a later study that
reported detecting glyburide in the cord blood at concen-
trations around 70 % of those in maternal blood.72
Metformin is a biguanide blood glucose-lowering
agent that acts by reducing hepatic gluconeogenesis. In
contrast with glyburide, metformin does not carry an
increased risk of hypoglycemia and weight gain. Metfor-
min is known to cross the placental barrier, with the
fetus being exposed to levels of metformin similar to
those in the mother.73
Short-term effects of glyburide
The ﬁrst major RCT to compare glyburide and insulin in
GDM was conducted by Langer et al. in 2000.71 In total,
404 women with GDM between 11 and 33weeks gesta-
tion were randomly assigned to receive glyburide or insu-
lin. The primary endpoint was glycemic control and the
secondary endpoints included perinatal complications.
Glycemic control and perinatal outcomes were similar
in both groups. There was less maternal hypoglycemia
in the glyburide group (2 % vs 20 %). In 4 % of women
in the glyburide group, this medication failed to produce
good glycemic control, and these women needed addi-
tional insulin.71
Since the RCT by Langer et al., numerous trials and
cohort studies have investigated the effects of glyburide
in GDM. A recent and well-conducted meta-analysis
by Balsells et al.74 summarized the short-term outcomes
of RCTs that compared glyburide or metformin with
insulin or with each other. The analysis included seven
trials that compared glyburide with insulin and demon-
strated that glyburide was associated with a higher birth
weight, an almost threefold higher risk of macrosomia,
and a twofold higher risk of neonatal hypoglycemia.74
The ﬁndings of Balsells et al.74 are comparable with
those of an earlier meta-analysis conducted by Zeng
et al.75 However, this earlier study concluded that
glyburide is as effective as insulin, while also reporting
a higher risk of neonatal hypoglycemia, high birth
weight, and macrosomia.75
Balsells et al.74 only included two studies that com-
pared metformin with glyburide and found metformin
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to be associated with less maternal weight gain, lower
birth weight, less macrosomia, and fewer LGA neonates.
Metformin was associated with slightly higher fasting
blood glucose levels and higher treatment failure com-
pared with glyburide.74
In summary, the evidence available from clinical
studies does not support the use of glyburide in GDM,
especially if metformin or insulin is available.
Short-term effects of metformin
Since 2007, evidence for the efﬁcacy and safety of
metformin use in pregnancy has been reinforced by the
results of several RCTs and meta-analyses.74,76–80 In
2013, the ﬁrst meta-analysis was conducted by Gui
et al.76; this study included ﬁve RCTs81–85 that compared
the effects of metformin with those of insulin therapy in
terms of glycemic control and maternal and neonatal
outcomes in GDM. Although Gui et al.76 reported no
differences between metformin and insulin in terms of
glycemic control and neonatal outcomes (birth weight,
LGA neonates, hypoglycemia, shoulder dystocia, and
cesarean delivery), rates of preterm birth were found to
be increased for metformin. Conversely, compared with
insulin therapy, metformin was associated with less
maternal weight gain and lower rates of pregnancy-
induced hypertension, the latter thought to be explained
by insulin-mediated sodium retention.76
Recently, ﬁve other meta-analyses have been pub-
lished comparing metformin and insulin therapy in
GDM.74,77–80 The meta-analyses by Poolsup et al.,77
Balsells et al.,74 and Gui et al.76 included the same RCTs
and found comparable results. The main difference
between these meta-analyses was that Poolsup et al.77
and Balsells et al.74 included an additional RCT86; they
also did not address exactly the same outcomes: Poolsup
et al.77 had no information on maternal weight gain and
Balsells et al.74 added additional outcomes, including
severe neonatal hypoglycemia and maternal total weight
gain. In this respect, Balsells et al.74 reported lower oc-
currence of severe neonatal hypoglycemia and a lower
maternal total weight gain in the metformin group. The
other three meta-analyses78–80 included the aforemen-
tioned RTCs as well as additional RCTs.87–89
On the basis of current evidence, it seems that metfor-
min may have some beneﬁts with short-term neonatal
outcomes similar to those for insulin therapy. However,
the higher risk of preterm birth in metformin treatment
is a point of concern that should be addressed in further
studies.
Long-term effects of metformin
Unfortunately, little is known about the long-term
effects of metformin in GDM. To date, several studies
have investigated the long-term effects of metformin
use in pregnancy on the subsequent growth and develop-
ment of the children.90–93 In 2011, the results of a 2-year
follow-up study of offspring were reported by the
Metformin in Gestational Diabetes (MiG) Trial. The
aim of that study was to compare the results of metfor-
min and insulin treatment in terms of body composition
and measures of adiposity in the children of women who
participated in the MiG trial.83,92 Children who were
exposed to metformin in utero had larger subscapular
and biceps skin folds than the offspring of mothers who
received insulin. The study suggests that metformin use
is associated with more fat being stored in subcutaneous
sites and perhaps less accumulation of ectopic or visceral
fat.92 The study found no difference in total or percen-
tage body fat between the children exposed to metformin
or insulin.92 One other follow-up study found that
children exposed to metformin were heavier at the age
of 12months and were both taller and heavier at
18months.90 However, in the multivariate regression
analysis, maternal body mass index (BMI) was the only
risk factor predicting a child being overweight or obese
at the age of 18months. Compared with insulin expo-
sure, the study found no adverse effects of prenatal
metformin exposure on motor, linguistic, or social deve-
lopment of the offspring during the ﬁrst 18months of
life.90
Another two follow-up studies of offspring and their
mothers were from an RCT conducted in women with
polycystic ovary syndrome who had been treated with
metformin or placebo during pregnancy.91,93 The ﬁrst
study,93 with a 1-year follow-up, showed that women
who received a placebo during their pregnancy had lost
more weight and had a lower BMI 1 year after delivery
than women who received metformin during their preg-
nancy. However, the women in the metformin group
gained less weight during their pregnancy. The offspring
exposed to metformin in utero had a higher body weight
at 1 year of age than those exposed to placebo.93 In
another study,91 the same authors performed a small
follow-up study of the offspring at the age of 8 years.
At that age there were no differences in height, weight,
body composition, and insulin resistance. However, the
children exposed to metformin in utero had higher
fasting glucose levels, higher systolic blood pressure,
and lower low-density lipoprotein cholesterol.91
There appears to be an urgent need for longer follow-
up studies assessing the true effect of metformin in a
larger offspring cohort at least until adolescence or
adulthood.
Studies on the effects of metformin during pregnancy
in humans have reported no harmful effects or terato-
genicity.94,95 However, animal studies have shown that
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metformin may harm the male reproductive system.
Tartarin et al.96 investigated both testicular deve-
lopment and function in the offspring of mice admin-
istered metformin during pregnancy. As well as
analyzing embryonic mice testes in vivo, that study in-
cluded human and mouse in vitro models. The results
showed that, in vitro, metformin reduced testosterone
secretion by decreased mRNA expression involved in
steroid production. In vivo, the number of Sertoli cells
was slightly reduced. The number of Leydig cells,
which produce androgens, including testosterone, was
diminished in the fetal period. The study showed that
metformin has detrimental effects on the developing
fetal testis.96
Other studies on the possible endocrine-disrupting
effects of metformin on male reproduction have been
performed in adult male ﬁsh. Because metformin is a
widely used medication in T2DM patients and is not
metabolized by the human body, high amounts are
commonly found in wastewater and surface water. The
medication is apparently not fully removed by wastewa-
ter treatment processes and is thought to be affecting the
health of ﬁsh populations. Recent studies have shown
that metformin can cause intersex in ﬁsh and cause male
ﬁsh to produce eggs.97 This environmental pollution
clearly illustrates that more studies are needed to investi-
gate the possible endocrine-disrupting effects of metfor-
min on vertebrate development and male fertility.
Despite the fact that the use of metformin in GDM is
questionable, especially because of the lack of long-term
safety data in offspring, metformin has already been
incorporated into at least two sets of guidelines. The
National Institute for Heath and Care Excellence
(NICE) guideline (UK) recommends the use of metfor-
min or insulin if lifestyle interventions fail to control
glycemic levels98; the American College of Obstetricians
and Gynecologists guideline also recommends the use of
metformin in GDM.99
Long-term effects of GDM
In recent years there has been increasing concern that
GDM may also be associated with long-term conse-
quences for the mother and child. Metabolic changes in
the mother during pregnancy can lead to structural and
functional adaptations during the development of the
fetus, with potential consequences for growth and
metabolism in the child’s later life. This phenomenon is
called fetal programming and was ﬁrst introduced by
Hales and Barker.100 These authors found that babies
who grow less well due to starvation in utero were more
likely to become overweight and develop T2DM and
cardiovascular diseases in adulthood.100
To date, several studies have investigated the asso-
ciation between maternal diabetes and the consequences
for offspring in later life. These studies have predomi-
nantly shown that maternal diabetes is associated with
obesity and T2DM in the offspring in later life.8,101–103
Animal models have also shown that intrauterine
exposure to mild maternal DM during pregnancy is
associated with T2DM, insulin resistance, and obesity
in the offspring.104 However, in animal studies it is
easier to study the precise effect of maternal glucose levels
on fetal development than in human studies. It is also eas-
ier to control for the main confounders, such as genetic
susceptibility and postnatal environmental inﬂuences.
Several systematic reviews have summarized evidence
from studies on the long-term consequences for
offspring of women with GDM. However, in terms of
an association between GDM and overweight and
obesity in the offspring, the results of the reviews were in-
consistent.105,106 In a recent critical review by Donavan
and Cundy,107 there was no robust evidence found that
exposure to hyperglycemia in utero increases the risk of
obesity and diabetes in the offspring. These authors sug-
gested that the increased risk of obesity seen in the off-
spring of women with GDM may be explained by
confounding factors, such as parental obesity (Fig. 1).
Figure 1 Fetal programming in gestational diabetes mellitus. GDM, gestational diabetes mellitus; T2DM, type 2 diabetes mellitus.
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There is a need for more research into GDM, and
especially for long-term studies into the program-
ming and development of offspring who have been
exposed prenatally to mild or moderate hyperglyce-
mia that include adequate controls for confounding
factors.
Even though in most women with GDM glucose
values normalize after delivery, it is well known that
women with a history of GDM are at increased risk for
impaired glucose tolerance and for developing T2DM
postpartum.108–110 Studies have shown that the risk of
developing T2DM may be as high as 50 % in the 5–
10 years after GDM.108,109 Therefore, it is important
that we recognize persistent glucose intolerance and di-
agnose T2DM as early as possible in these women in or-
der to start early interventions and to prevent long-term
DM complications. Prevention strategies, such as life-
style interventions, could have a considerable positive
public health impact.111
Future directions and challenges
There is clearly a need for more GDM research. Gesta-
tional diabetes mellitus is a global health problem, not
only because its prevalence is high and on the increase,
but also because of the potential implications for the
health of mothers and their offspring. There is a clear
need for a set of globally uniform guidelines on the diag-
nosis of and treatment strategy for GDM. Currently,
guidelines differ with regard to diagnostic cut-off
criteria, most likely prompted by the fear of the costs
and healthcare efforts that would be attached to any
strengthening of diagnostic criteria. Endeavors to adopt
the criteria proposed by IADPSG will warrant large
cohort studies in GDM in order to provide both medical
and economic justiﬁcations for such a change.
The treatment of GDM is also accompanied by both
certainties and caveats. There is no speciﬁc guideline on
dietary treatment and studies are scarce, although there
is general consensus that excessive carbohydrate intake
should limited and distributed over meals to lower
glycemic excursions. However, it is unknown whether
carbohydrate restriction is actually beneﬁcial in GDM,
as has been indicated by a number of studies on this
topic. Although these studies showed promising results
on glycemic control and the reduced risk of later
developing T2DM, there is a clear need for further
investigating the beneﬁts and perils of carbohydrate
restriction in GDM both during pregnancy and
afterwards.
With the exception of speciﬁc issues related to the use
of insulin in GDM, drug treatment remains contentious
and the advice provided in guidelines is highly variable.
In terms of the use of oral blood glucose-lowering
agents, the risk of neonatal hypoglycemia and increased
neonatal birth weights does not support use of glyburide
in GDM. The use of metformin seems promising and has
already been incorporated into several guidelines. The
uncertainties related to metformin use are a possible risk
of premature delivery and concerns of the long-term
safety regarding male fertility, and there is a particular
need for studies regarding fetal programming and
development in the offspring.
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